Advocacy intelligence hub — real-time data for patient organizations
University Hospital, Rouen — PHASE2
Merck Sharp & Dohme LLC — PHASE3
Merck Sharp & Dohme LLC — PHASE2
University of Cologne — PHASE3
Invicro — EARLY_PHASE1
AstraZeneca — PHASE1
University Medical Centre Ljubljana — NA
BioNTech SE — PHASE1, PHASE2
Merck Sharp & Dohme LLC — PHASE3
Merck Sharp & Dohme LLC — PHASE2
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Browse all Autosomal dominant multiple pterygium syndrome news →
Arun Rajan, M.D., M.D
National Cancer Institute (NCI)
📍 BETHESDA, MD
Randall J Bateman, MD, MD
Washington University School of Medicine
📍 SAINT LOUIS, MO
BioNTech Responsible Person
BioNTech SE
Mark Jones, MD
Incyte Corporation
Ozlem Goker-Alpan, MD
Lysosomal & Rare Disorders Research & Treatment Center, Inc.
📍 Fairfax, Virginia
Yue He, M.D.
the Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
📍 ISSAQUAH, WA
View all Autosomal dominant multiple pterygium syndrome specialists →